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1007MP-121 Tissue Factor Elicits Thrombln Generetlon in Human 
Atheroeclerotic Plaques 
Pier Angelica Merlini, Maurizio Ferrario, Ezio Bramucci, Luigi Angoli, Alessandra 
Repetto, Umborto Canosi, Diego Ardissino, Cardiology, Policlinico San Matteo, Pavia, 
Italy, Cardiology,, Ospedale Niguarda, Milano, Italy, 
Background: Tissue Factor (TF, the initiator of blood coagulation) is more concentrated 
in coronary atherosclerotic plaques of patients (pts) with acute coronary syndromes 
(ACS) than in coronary plaques obtained from pts with stable angina pectoris (AP). How- 
ever, it is not clear whether this difference is associated with an in vivo increased throm- 
botic response to plaque rupture. The aim of the study was to evaluate the thromboganic 
potential of coronary plaques of pts with either ACS or stable AP, by measuring the local 
thrombin generation under basel conditions and after plaque rupture obtained by direc- 
tional coronary atherectomy (DCA). 
Methods: We studied 40 consecutive pts undergoing DCA: 22 pts with stable AP, 18 pts 
with ACS (12 with unstable AP, 6 with AMI). Blood samples were directly obtained, by a 
specially designed sampling catheter, proximally and distally to the coronary atheroscle- 
rotic plaque, both before and after the procedure. Plasma levels of prothrombin fragment 
1+2 (F1+2, a marker of thrombin generation) have been quantified by double antibody 
redioimmunoassay. 
Results: 
ABSTRACTS - Hypertension, Vascular Disease, and Prevention JACC March 6, 2002 
Stable AP ACS p 
N= 22 N= 18 
Before DCA 
F1 +2 proximal 0.95 (0.78-1.87) 1.16 (0.86-1.49) ns 
F1+2 distal 1.00 (0.7-2.0) 1.50 (1.15-2.07) 0.0045 
Change -0.065 (-0.22-0.15) 0.37 (0.04-0.63) 0.0021 
After DCA 
F1+2 proximal 1.06 (0.86-1.39) 1.03 (0.99-1.68) ns 
F1+2 distal 0.97 (0.77-1.24) 1.31 (1.04-2.02) 0.027 
Change 0.01 (-0.06-0.14) 0.25 (0.02-0.42) 0.036 
Data are expressed as nrool/L; medians and interquartile ranges are reported. 
Conclusion: TF-dch plaques of pts with ACS are associated with a local increase in 
thrombin generation not detected in pts with stable AP, both under baseline conditions 
and after disruption by DCA. This data suggest a link between plaque composition and 
thrombogenicity, invivo. 
9:12 a.m. 
1007MP-122 Increased Circulating Tissue Factor and Blood 
Thrombogeniclty in Type-2 Diabetes 
Antonia Sambola. James Hathcock, Julio Osende, Yale Nemerson, Valentin Fuster, Jill 
Crandall, Juan Jose Badimon, Mount Sinai School of Medicine, New York, New York. 
Background: Several studies suggest a role for circulating tissue factor activity (TF-AcT) 
in atherothrombotic diseases. Type-2 Diabetes Mellitus (T2DM) is associated with a high 
rate of thrombotic omplications. We have previously shown an increase in the blood 
thrombogenicity (BT) in poorly controlled T2DM patients. Improvements in glycamic con- 
trol were associated with decreases in BT. Our objective in this study was to investigate 
1) whether T2DM is associated with increased circulating TF-AcT and 2) if an improve- 
ment in glycemic control is correlated with TF-AcT levels. 
Methods: Poorly controlled T2DM patients (n=36) maintaining their current hypoglyce- 
mic therapies, were randomized into diet modification plus troglitazona or diet modifica- 
tion plus placebo for 3 months. Cimulating TF-AcT was determined using a modification 
of a previously described technique, in which an immobilized antibody was used to cap- 
ture solubilized TF. TF-AcT was determined by measuring FXa generation. BT was 
assessed by the area of platalet-thrombus formation in the Badimon perfusion chamber. 
Improvement in glycamic control was considered a decreased HBAlc~- 0.5. 
Results: T2DM patients showed a significantly higher circulating TF-AcT plasma level, 
both at baseline and after treatment (370±161 vs 286±163 FXa (pM/min), p=0.0001) than 
healthy volunteers (211:t:60, FXa (pM/min), p=0.0001, n=t5). Patients with improvement 
in glycemic control showed a significant reduction in circulating TF activity (362~135 vs 
243±74 FXa (pM/min), p=0.0001), independent of the treatment group. A similar pattam 
was observed in BT (15.445±1130 vs 12072±596 pm/mm2, p=0.01). The reduction in 
HbAlc was significantly correlated to the reduction in TF-AcT levels (p=0.014). 
Conclusions: Our data indicate 1) high levels of circulating TF-AcT are present in T2DM 
patients, 2) changes in BT are associated with circulating TF-AcT levels in patients with 
T2DM. 3) Improvement in the glycamic control was associated with decreased TF-AcT 
levels. These findings suggest that the hyperthrombotic state associated with T2DM may 
be mediated by high levels of TF-AcT and these observations may help to develop future 
therapies in T2DM patients. 
9:24 a.m. 
1007MP-123 Simvsetatin and Pravaststin Inhibit the Synthesis of 
Tissue Factor In Smooth Muscle Cells In Vitro 
Plinio Cirill0, Paolo Golino, Psolo Calabrb, Massimo Regni, Lavinia Forte, Salvatore De 
Rosa, Massimo Chiariello, Division of Cardiology, University of Naples =Federico I1", 
Naples,/ta/y 
Background: Tissue factor (TF), a key initiator of blood coagulation, is widely expressed 
in atherosclerotic plaques, where it represents a major determinant of plaque thromboge- 
nicity. Statins reduce the incidence of acute coronary events, even in patients with nor- 
real cholesterol plasma levels. Methods: To verity whether statins reduce TF expression 
in smooth muscle cells (SMCs), SMCs from rabbit aortas, made quiescent by serum dep- 
rivation, were pretreated with either simvastatin (S; 5 pg/ml), pravastatin (P; 5 IJg/ml), or 
placebo. SMCs were stimulated for 30 min with lipopolysaccharide (LPS, 50 I~g/ml), a 
stimulus able to induce TF expression. TF activity was measured by a chromogenic 
assay and TF-mRNA levels were evaluated by a semi-quantitative RT-PCR. Results: 
LPS induced a significant TF protein expression, as compared to unstimulated cells (con- 
trol). Both simvastatin and pravastatin completely inhibited TF expression (*= p<0.01 vs 
LPS). 
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TF-mRNA levels increased significantly after LPS to 3.5±0.3 fold with respect to unstimu- 
lated cells, while they did not change significantly in cells pretreatred with S or P (1.1 ±0.1 
and 1.2±0.1 fold, respectively, as compared to their respective controls). Conclusion: S 
and P both reduce TF m-RNA and protein expression in SMCs stimulated with LPS, 
probably by inhibiting TF-mRNA transcription. This phenomenon might partly explain the 
benefical effects of statins in patients with coronary atherosclerosis. 
9:36 a.m. 
1007MP-124 Tissue Factor Expression Is Increased in Cardiac 
Transplant Recipients Who Develop Cardiac Transplant 
Arteriopathy 
Michael H. Yen, Guy Piikington, Norman Ratiiff, Patrick M McCarthy, James B. Young, 
Randall C. Starling, Guy M. Chisotm, Marc S. Penn, The ClevelandC/inic Foundation, 
Cleveland, Ohio. 
Background: We have demonstrated that oxidant stress upregulates tissue factor (TF) 
activity in smooth muscle (SMC) end endothelial cells (EC) by an antioxidant inhibitable 
mechanism. These data, along with the observations that (i) fibrin deposition and oxidant 
stress predict transplant arteriopathy (TA) and that (ii) TA progression may be inhibited 
by entioxidants, lead us to hypothesize that TF could play a role in TA. 
Methods: We developed a TF scoring index for TF expression in the arterioles in right 
heart biopsies (RHB). We studied 63 consecutive patients who underwent routine RHB 
and surveillance angiography >2 years (n=35), <2 years (n=28) after transplant. 
Results: Our data demonstrate that the TF score is predictive of TA. We found no corre- 
lation between TF expression and RHB rejection score. RHB specimens from patients 
without TA were more likely to have a low TF score; similarly specimens from patients 
with TA were more likely to have a high TF score (Table, p=0.005). TF score from biopsy 
specimens from patients within 2 years after transplant had a positive predictive value of 
89% and a negative predictive value of 100%. 
Conclusion: Our data demonstrate a correlation between increased TF expression and 
the development of TA. TF causes increased local thrombin production leading to (i) 
microvascular thrombosis, (ii) SMC proliferation, and (iii) EC activation. Furthermore, our 
data suggests that TF could be the target of antioxidant herapy, as well as future thera- 
pies directed at TA. 
>2 years (n=35) < 2 years (n=28) 
TA TF Low TF High TF Low TF High 
No (%) 78.9 21.1 87.5 12.5 
Yes (%) 31.3 68.9 0 100 
9:48 a.m. 
1007MP-125 Inhibitory Effect of C-Rseotive Protein on the Release of 
Tissue Factor Pathway Inhibitor From Human 
Endothelial Cells: Reversal by Low Molecular Weight 
Heparin 
Shaker A. Mousa, Jeffrey M. Bozarth, DuPont, Wilmington, Delaware. 
Elevated C-reactive protein (CRP) is associated with a higher risk of cardiac events in 
patients with acute coronary syndrome. Elevated CRP levels has been shown to promote 
the expression of tissue factor in monocytes, which may lead to fibrin deposition and 
